Status:
UNKNOWN
Effect of Rosiglitazone on ADMA in Critical Illness
Lead Sponsor:
Amsterdam UMC, location VUmc
Conditions:
Critical Illness
Multiple Organ Failure
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether Rosiglitazone,decreases the ADMA concentration and thereby increases the arginine/ADMA ratio of critically ill patients.
Detailed Description
Endothelial vasodilatation dysfunction precedes the development of arteriosclerosis. The endothelium plays a pivotal role in the control of the vascular tone by releasing nitric oxide (NO). The amino ...
Eligibility Criteria
Inclusion
- critically ill patients
- age between 18 and 75 years
- SOFA score \> 7
Exclusion
- history of Diabetes mellitus
- history of hypercholesterolemia
- history of hyperhomocysteinemia
- impaired hepatic function
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00409097
Start Date
April 1 2006
End Date
December 1 2007
Last Update
December 8 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VU University Medical Center
Amsterdam, Netherlands, 1081 HV